Compare RDZN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RDZN | RFL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.2M | 92.6M |
| IPO Year | 2021 | 2017 |
| Metric | RDZN | RFL |
|---|---|---|
| Price | $1.40 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 247.2K | 84.8K |
| Earning Date | 02-12-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.12 | 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,021,792.00 | $917,000.00 |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 24.21 | ★ 43.96 |
| 52 Week Low | $0.81 | $1.12 |
| 52 Week High | $2.56 | $3.96 |
| Indicator | RDZN | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 47.94 |
| Support Level | $1.38 | $1.21 |
| Resistance Level | $1.47 | $3.96 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 96.45 | 39.22 |
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.